Annotation Detail

Information
Associated Genes
ALK
Associated Variants
ALK EML4-ALK E6;A20
Associated Disease
lung non-small cell carcinoma
Source Database
CIViC Evidence
Description
Ba/F3 cells transduced with EML4-ALK variants v1 (E13;A20), v2 (E20;A20), v3a (E6;A20) and v3b (E6ins33;A20) showed differential sensitivity to both crizotinib and TAE684, with variant 3a (E6;A20) being the least sensitive. The authors suggest that the type/structure of ALK fusion may have some impact on patient outcome in targeted therapy.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1197
Gene URL
https://civic.genome.wustl.edu/links/genes/1
Variant URL
https://civic.genome.wustl.edu/links/variants/503
Rating
2
Evidence Type
Predictive
Disease
Lung Non-small Cell Carcinoma
Evidence Direction
Does Not Support
Drug
Crizotinib
Evidence Level
D
Clinical Significance
Sensitivity/Response
Pubmed
22912387
Drugs
Drug NameSensitivitySupported
CrizotinibSensitivityfalse